News - Rituxan

Filter

Current filters:

Rituxan

Popular Filters

Pipeline innovation bodes well for systemic lupus erythematosus market

18-02-2014

While the systemic lupus erythematosus (SLE) treatment market is predominantly limited to GlaxoSmithKline’s…

AmgenAnti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineImmuPharmaLupuzorLymphoCideMarkets & MarketingPharmaceuticalRituxanRoche

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

Roche’s Gazyva slows disease worsening compared to MabThera/Rituxan

07-11-2013

Swiss drug major Roche (ROG: SIX) has announced new data from the second stage of the CLL11 Phase III…

EuropeGazyvaMabTheraOncologyPharmaceuticalResearchRituxanRoche

Roche’s Gazyva gains FDA approval of CLL

Roche’s Gazyva gains FDA approval of CLL

04-11-2013

The US Food and Drug Administration late Friday approved Roche’s Gazyva (obinutuzumab), also known…

Biogen IdecBiotechnologyGazyvaGenentechMabTheraNorth AmericaobinutuzumabOncologyRegulationRituxanRoche

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

US FDA warns of hepatitis B reactivation risk with Arzerra and Rituxan

26-09-2013

The US Food and Drug Administration has approved changes to the prescribing information of the immune-suppressing…

Anti-Arthritics/RheumaticsArzerraBiogen IdecGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRituxanRoche

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Biogen Idec beats expectations in 2nd-qtr, helped by Tecfidera launch

25-07-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) has reported second quarter 2013 total revenues of $1.7 billion,…

AvonexBiogen IdecBiotechnologyFinancialNorth AmericaRituxanTecfideraTysabri

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Roche's obinutuzumab significantly improves PFS in chronic lymphocytic leukemia

04-02-2013

Swiss drug major Roche (ROG: SIX) says that the first stage of a Phase III study with its investigational…

BiotechnologyGA101MabTheraobinutuzumabOncologyPharmaceuticalResearchRituxanRoche

Back to top